Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy
Fetal growth restriction (FGR) affects about 3% to 8% of pregnancies, leading to higher perinatal mortality and morbidity. Current strategies for detecting fetal growth impairment are based on ultrasound inspections. However, antenatal detection rates are insufficient and critical in countries with...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/5/1374 |
| _version_ | 1797568612144250880 |
|---|---|
| author | Charles A. Okai Manuela Russ Manja Wölter Kristin Andresen Werner Rath Michael O. Glocker Ulrich Pecks |
| author_facet | Charles A. Okai Manuela Russ Manja Wölter Kristin Andresen Werner Rath Michael O. Glocker Ulrich Pecks |
| author_sort | Charles A. Okai |
| collection | DOAJ |
| description | Fetal growth restriction (FGR) affects about 3% to 8% of pregnancies, leading to higher perinatal mortality and morbidity. Current strategies for detecting fetal growth impairment are based on ultrasound inspections. However, antenatal detection rates are insufficient and critical in countries with substandard care. To overcome difficulties with detection and to better discriminate between high risk FGR and low risk small for gestational age (SGA) fetuses, we investigated the suitability of risk assessment based on the analysis of a recently developed proteome profile derived from maternal serum in different study groups. Maternal serum, collected at around 31 weeks of gestation, was analyzed in 30 FGR, 15 SGA, and 30 control (CTRL) pregnant women who delivered between 31 and 40 weeks of gestation. From the 75 pregnant women of this study, 2 were excluded because of deficient raw data and 2 patients could not be grouped due to indeterminate results. Consistency between proteome profile and sonography results was obtained for 59 patients (26 true positive and 33 true negative). Of the proteome profiling 12 contrarious grouped individuals, 3 were false negative and 9 were false positive cases with respect to ultrasound data. Both true positive and false positive grouping transfer the respective patients to closer surveillance and thorough pregnancy management. Accuracy of the test is considered high with an area-under-curve value of 0.88 in receiver-operator-characteristics analysis. Proteome profiling by affinity-mass spectrometry during pregnancy provides a reliable method for risk assessment of impaired development in fetuses and consumes just minute volumes of maternal peripheral blood. In addition to clinical testing proteome profiling by affinity-mass spectrometry may improve risk assessment, referring pregnant women to specialists early, thereby improving perinatal outcomes. |
| first_indexed | 2024-03-10T19:59:25Z |
| format | Article |
| id | doaj.art-7577d44838454ffd914900b8b427512b |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T19:59:25Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-7577d44838454ffd914900b8b427512b2023-11-19T23:41:37ZengMDPI AGJournal of Clinical Medicine2077-03832020-05-0195137410.3390/jcm9051374Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during PregnancyCharles A. Okai0Manuela Russ1Manja Wölter2Kristin Andresen3Werner Rath4Michael O. Glocker5Ulrich Pecks6Proteome Center Rostock, University Medicine and Natural Science Faculty, University of Rostock, 18051 Rostock, GermanyProteome Center Rostock, University Medicine and Natural Science Faculty, University of Rostock, 18051 Rostock, GermanyProteome Center Rostock, University Medicine and Natural Science Faculty, University of Rostock, 18051 Rostock, GermanyDepartment of Obstetrics and Gynecology, Medical Faculty, University of Schleswig-Holstein, Campus Kiel, 24105 Kiel, GermanyDepartment of Obstetrics and Gynecology, Medical Faculty, University of Schleswig-Holstein, Campus Kiel, 24105 Kiel, GermanyProteome Center Rostock, University Medicine and Natural Science Faculty, University of Rostock, 18051 Rostock, GermanyDepartment of Obstetrics and Gynecology, Medical Faculty, University of Schleswig-Holstein, Campus Kiel, 24105 Kiel, GermanyFetal growth restriction (FGR) affects about 3% to 8% of pregnancies, leading to higher perinatal mortality and morbidity. Current strategies for detecting fetal growth impairment are based on ultrasound inspections. However, antenatal detection rates are insufficient and critical in countries with substandard care. To overcome difficulties with detection and to better discriminate between high risk FGR and low risk small for gestational age (SGA) fetuses, we investigated the suitability of risk assessment based on the analysis of a recently developed proteome profile derived from maternal serum in different study groups. Maternal serum, collected at around 31 weeks of gestation, was analyzed in 30 FGR, 15 SGA, and 30 control (CTRL) pregnant women who delivered between 31 and 40 weeks of gestation. From the 75 pregnant women of this study, 2 were excluded because of deficient raw data and 2 patients could not be grouped due to indeterminate results. Consistency between proteome profile and sonography results was obtained for 59 patients (26 true positive and 33 true negative). Of the proteome profiling 12 contrarious grouped individuals, 3 were false negative and 9 were false positive cases with respect to ultrasound data. Both true positive and false positive grouping transfer the respective patients to closer surveillance and thorough pregnancy management. Accuracy of the test is considered high with an area-under-curve value of 0.88 in receiver-operator-characteristics analysis. Proteome profiling by affinity-mass spectrometry during pregnancy provides a reliable method for risk assessment of impaired development in fetuses and consumes just minute volumes of maternal peripheral blood. In addition to clinical testing proteome profiling by affinity-mass spectrometry may improve risk assessment, referring pregnant women to specialists early, thereby improving perinatal outcomes.https://www.mdpi.com/2077-0383/9/5/1374FGRSGAproteome profilingaffinity-MSpregnancy complicationsapolipoproteins |
| spellingShingle | Charles A. Okai Manuela Russ Manja Wölter Kristin Andresen Werner Rath Michael O. Glocker Ulrich Pecks Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy Journal of Clinical Medicine FGR SGA proteome profiling affinity-MS pregnancy complications apolipoproteins |
| title | Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy |
| title_full | Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy |
| title_fullStr | Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy |
| title_full_unstemmed | Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy |
| title_short | Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy |
| title_sort | precision diagnostics by affinity mass spectrometry a novel approach for fetal growth restriction screening during pregnancy |
| topic | FGR SGA proteome profiling affinity-MS pregnancy complications apolipoproteins |
| url | https://www.mdpi.com/2077-0383/9/5/1374 |
| work_keys_str_mv | AT charlesaokai precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy AT manuelaruss precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy AT manjawolter precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy AT kristinandresen precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy AT wernerrath precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy AT michaeloglocker precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy AT ulrichpecks precisiondiagnosticsbyaffinitymassspectrometryanovelapproachforfetalgrowthrestrictionscreeningduringpregnancy |